Literature DB >> 15345287

Mutant N-ras preferentially drives human CD34+ hematopoietic progenitor cells into myeloid differentiation and proliferation both in vitro and in the NOD/SCID mouse.

Sylvie W Shen1, Alla Dolnikov, Toby Passioura, Michelle Millington, Simon Wotherspoon, Alison Rice, Karen L MacKenzie, Geoff Symonds.   

Abstract

OBJECTIVES: Ras oncogene mutations are the most frequently observed genetic abnormality (20-40% of patients) in acute myeloid leukemia (AML), and in the preleukemic conditions myelodysplastic syndrome (MDS) and myeloproliferative disorder (MPD). We have previously shown that mutant N-ras (N-rasm) can induce myeloproliferative disorders and apoptosis in a murine reconstitution system. In the present study we investigated the effect of N-rasm in human primary hematopoietic progenitor cells (HPC).
METHODS: Cord blood CD34+ hematopoietic progenitor cells (HPC) were transduced with retroviral vectors containing green fluorescence protein (GFP) alone, or in combination with N-rasm. Cells were then cultured in vitro with a cytokine supplement or cocultured with murine stroma MS-5 cells. The in vivo behavior of transduced cells was examined in the NOD/SCID mouse model.
RESULTS: N-rasm-transduced cells exhibited greater proliferative capacity; a higher frequency of granulocyte-macrophage colony-forming unit (CFU-GM); and an increase in myelomonocytic lineage cells with a concomitant decrease in lymphoid and erythroid cells. Analysis of transduced HPC in NOD/SCID mice revealed higher bone marrow engraftment by N-rasm HPC and increased numbers of myeloid lineage cells.
CONCLUSIONS: The results demonstrate that N-rasm in HPC induces myeloproliferation both in vitro and in the NOD/SCID mouse model as a primary event that does not appear to be dependent on cooperating transforming events.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15345287     DOI: 10.1016/j.exphem.2004.06.001

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  11 in total

1.  N-Ras(G12D) induces features of stepwise transformation in preleukemic human umbilical cord blood cultures expressing the AML1-ETO fusion gene.

Authors:  Fu-Sheng Chou; Mark Wunderlich; Andrea Griesinger; James C Mulloy
Journal:  Blood       Date:  2011-01-03       Impact factor: 22.113

2.  Activated k-ras, but not h-ras or N-ras, regulates brain neural stem cell proliferation in a raf/rb-dependent manner.

Authors:  R Hugh F Bender; Kevin M Haigis; David H Gutmann
Journal:  Stem Cells       Date:  2015-06       Impact factor: 6.277

3.  Oncogenic NRAS hyper-activates multiple pathways in human cord blood stem/progenitor cells and promotes myelomonocytic proliferation in vivo.

Authors:  Tongjie Wang; Chen Li; Chengxiang Xia; Yong Dong; Dan Yang; Yang Geng; Jizhen Cai; Jing Zhang; Xiangzhong Zhang; Jinyong Wang
Journal:  Am J Transl Res       Date:  2015-10-15       Impact factor: 4.060

4.  KRAS(G12V) enhances proliferation and initiates myelomonocytic differentiation in human stem/progenitor cells via intrinsic and extrinsic pathways.

Authors:  Szabolcs Fatrai; Djoke van Gosliga; Lina Han; Simon M G J Daenen; Edo Vellenga; Jan Jacob Schuringa
Journal:  J Biol Chem       Date:  2010-12-17       Impact factor: 5.157

5.  RAS oncogene suppression induces apoptosis followed by more differentiated and less myelosuppressive disease upon relapse of acute myeloid leukemia.

Authors:  Won-Il Kim; Ilze Matise; Miechaleen D Diers; David A Largaespada
Journal:  Blood       Date:  2008-10-24       Impact factor: 22.113

6.  Overexpression of Rheb2 enhances mouse hematopoietic progenitor cell growth while impairing stem cell repopulation.

Authors:  Timothy B Campbell; Sunanda Basu; Giao Hangoc; Wen Tao; Hal E Broxmeyer
Journal:  Blood       Date:  2009-08-18       Impact factor: 22.113

7.  Overexpression of ERG in cord blood progenitors promotes expansion and recapitulates molecular signatures of high ERG leukemias.

Authors:  M L Tursky; D Beck; J A I Thoms; Y Huang; A Kumari; A Unnikrishnan; K Knezevic; K Evans; L A Richards; E Lee; J Morris; L Goldberg; S Izraeli; J W H Wong; J Olivier; R B Lock; K L MacKenzie; J E Pimanda
Journal:  Leukemia       Date:  2014-10-13       Impact factor: 11.528

8.  Oncogenic NRAS Primes Primary Acute Myeloid Leukemia Cells for Differentiation.

Authors:  Cornelia Brendel; Sabine Teichler; Axel Millahn; Thorsten Stiewe; Michael Krause; Kathleen Stabla; Petra Ross; Minh Huynh; Thomas Illmer; Marco Mernberger; Christina Barckhausen; Andreas Neubauer
Journal:  PLoS One       Date:  2015-04-22       Impact factor: 3.240

9.  Inducible expression of EVI1 in human myeloid cells causes phenotypes consistent with its role in myelodysplastic syndromes.

Authors:  Torsten A Konrad; Anna Karger; Hubert Hackl; Ilse Schwarzinger; Irene Herbacek; Rotraud Wieser
Journal:  J Leukoc Biol       Date:  2009-07-15       Impact factor: 4.962

10.  Oncogenic RAS enables DNA damage- and p53-dependent differentiation of acute myeloid leukemia cells in response to chemotherapy.

Authors:  Mona Meyer; Daniela Rübsamen; Robert Slany; Thomas Illmer; Kathleen Stabla; Petra Roth; Thorsten Stiewe; Martin Eilers; Andreas Neubauer
Journal:  PLoS One       Date:  2009-11-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.